|
Endpoint
|
Tumor cells in cervical lymph nodes
|
P value
|
Preoperative plasma EBV DNA
|
P value
|
|---|
|
Presence
|
Absence
|
Presence
|
Absence
|
|---|
|
Total (cases)
|
68
|
14
| |
36
|
46
| |
|
PFS
|
|
Failures [cases (%)]
|
39 (57.4)
|
2 (14.3)
|
0.008
|
22 (61.1)
|
19 (41.3)
|
0.031
|
|
3-year rate [% (95% CI)]
|
49.9 (37.6–62.2)
|
83.3 (62.1–100)
| |
43.7 (26.1–61.3)
|
61.1 (46.6–75.6)
| |
|
OS
|
|
Deaths [cases (%)]
|
21 (30.9)
|
0 (0.0)
|
0.014
|
13 (36.1)
|
8 (17.4)
|
0.020
|
|
3-year rate [% (95% CI)]
|
83.2 (73.6–92.8)
|
100
| |
79.2 (64.3–94.1)
|
90.7 (82.1–99.3)
| |
|
DMFS
|
|
Failures [cases (%)]
|
19 (27.9)
|
1 (7.1)
|
0.073
|
10 (27.8)
|
10 (21.7)
|
0.230
|
|
3-year rate [% (95% CI)]
|
79.6 (69.2–90.0)
|
91.7 (76.0–100)
| |
80.2 (65.9–94.5)
|
85.9 (75.3–96.5)
| |
|
LRRFS
|
|
Failures [cases (%)]
|
33 (48.5)
|
1 (7.1)
|
0.005
|
20 (55.6)
|
14 (30.4)
|
0.009
|
|
3-year rate [% (95% CI)]
|
53.9 (41.2–66.6)
|
91.7 (76.0–100)
| |
46.4 (28.4–64.4)
|
68.2 (53.7–82.7)
| |
|
LRFS
|
|
Failures [cases (%)]
|
19 (27.9)
|
1 (7.1)
|
0.102
|
13 (36.1)
|
7 (15.2)
|
0.017
|
|
3-year rate [% (95% CI)]
|
71.0 (59.6–82.4)
|
91.7 (76.0–100)
| |
61.1 (44.4–77.8)
|
84.9 (73.7–96.1)
| |
|
RRFS
|
|
Failures [cases (%)]
|
21 (30.9)
|
0 (0.0)
|
0.014
|
13 (36.1)
|
8 (17.4)
|
0.027
|
|
3-year rate [% (95% CI)]
|
73.0 (61.6–84.4)
|
100
| |
69.8 (52.9–86.7)
|
80.7 (68.5–92.9)
| |
- NPC nasopharyngeal carcinoma, PFS progression-free survival, OS overall survival, DMFS distant metastasis-free survival, LRRFS locoregional relapse-free survival, LRFS local relapse-free survival, RRFS regional relapse-free survival, CI confidence interval
- P values were calculated with the unadjusted log-rank test
